Sun Pharmaceutical Industries Limited has entered into agreements to acquire minority stake in Agatsa Software Private Limited and Remidio Innovative Solutions Private Limited.

Agasta Software is engaged in research, development and commercialization of medical devices in the diagnostic health segment by leveraging technology and R&D capabilities. The revenue from operations for FY 2021-22 was Rs. 44,05,485.

The company has agreed to acquire equity shares (up to 26.09%) of Agatsa Software Private Limited, which is an early-stage digital diagnostic devices company.

The acquisition in two tranches wherein Tranche 1 would be completed in February 2023 and Tranche 2 is expected to be completed by August 2023, subject to certain conditions. Tranche 1 is Rs. 8 crore and Tranche 2  is upto Rs. 22 crore, subject to certain conditions. 

Sun Pharmaceuticals has agreed to acquire equity shares (27.39%) of Remidio Innovative Solutions Private Limited, which provides innovative products enabling early detection of eye diseases.

The company provides innovative products enabling early detection of eye diseases. The revenue from operations for FY 2021-22 on consolidated basis was Rs. 26.61 crore.

The company has a subsidiary ‘Remidio Innovation Solutions Inc' in USA and ‘Medios Technologies Pte. Ltd in Singapore.